【指南与共识】| CPCC晚期前列腺癌中国专家共识——转移性激素敏感性前列腺癌起始应用新型内分泌治疗的全程管理（2022年版）_附属_肿瘤 (2025)

“ioncology”关注我们，

然后点右上角“…”菜单，选择“设为星标”

引用本文

中国前列腺癌研究协作组（CPCC），叶定伟，黄  健. CPCC晚期前列腺癌中国专家共识——转移性激素敏感性前列腺癌起始应用新型内分泌治疗的全程管理（2022年版）［J］. 中国癌症杂志, 2022, 32 (12): 1242-1259.

通信作者：叶定伟；黄 健。

通信作者简介

叶定伟，主任医师，教授，复旦大学附属肿瘤医院党委副书记，泌尿外科学科带头人，泌尿肿瘤多学科团队首席专家，上海市泌尿肿瘤研究所所长，复旦大学前列腺肿瘤研究所所长，中国抗癌协会泌尿男生殖系肿瘤专业委员会前任主任委员，中国临床肿瘤学会（CSCO）前列腺癌专家委员会主任委员， CSCO尿路上皮癌专家委员会副主任委员，CSCO肾癌专家委员会副主任委员，CSCO免疫治疗专家委员会副主任委员，中国肿瘤医院泌尿肿瘤协作组（UCOG）主任委员，中国抗癌协会常务理事，CSCO常务理事，中国抗癌协会泌尿男生殖系肿瘤专业委员会前列腺癌学组组长，美国国立综合癌症网络（NCCN）肾癌诊治指南中国版编写组副组长，NCCN前列腺癌、肾癌和膀胱癌亚洲诊治共识专家委员会委员，亚太前列腺癌学会（APPS）候任主任委员，亚太冷冻外科学会副会长，晚期前列腺癌亚太共识专家委员会委员，上海市医师协会泌尿外科医师分会副会长，前上海市抗癌协会理事长，国家自然科学基金二审专家，亚太前列腺癌学会（APPS）候任主席，Asian Journal of Andrology副主编，Prostate Cancer and Prostatic Disease、British Journal of Urology International编委。

通信作者简介

黄健，教授、主任医师、博士生导师、中山大学孙逸仙纪念医院泌尿外科主任、中华医学会泌尿外科学分会 、主任委员、中国医师协会医学机器人医师分会 副会长、中华医学会泌尿外科学分会 肿瘤学组组长、《中国泌尿外科和男科疾病诊断治疗指南》主编、《中华泌尿外科杂志》 总编辑、International Journal of Urology、Asian Journal of Urology、Journal of Endourology 等杂志编委。

CPCC晚期前列腺癌中国专家共识——转移性激素敏感性前列腺癌起始应用新型内分泌治疗的全程管理（2022年版）

中国前列腺癌研究协作组（CPCC），叶定伟1，黄  健2

1.复旦大学附属肿瘤医院泌尿外科，复旦大学上海医学院肿瘤学系，上海 200032；

2.中山大学孙逸仙纪念医院泌尿外科，广东 广州 510060

《CPCC晚期前列腺癌中国专家共识——转移性激素敏感性前列腺癌起始应用新型内分泌治疗的全程管理（2022年版）》讨论和审定的专家

（以姓氏拼音字母为序）

• 边家盛 | 山东省肿瘤医院
• 卞晓洁 | 复旦大学附属肿瘤医院
• 陈惠庆 | 山西省肿瘤医院
• 陈 鹏 | 新疆维吾尔自治区肿瘤医院
• 陈守臻 | 山东大学齐鲁医院
• 范 宇 | 北京大学第一医院
• 傅 斌 | 南昌大学第一附属医院
• 傅 强 | 山东省立医院
• 高 旭 | 上海长海医院
• 苟 欣 | 重庆医科大学附属第一医院
• 谷 江 | 贵州医科大学附属医院
• 郭剑明 | 复旦大学附属中山医院
• 何朝宏 | 河南省肿瘤医院
• 何志嵩 | 北京大学第一医院
• 胡 滨 | 辽宁省肿瘤医院
• 胡志全 | 华中科技大学同济医学院附属同济医院
• 金百冶 | 浙江大学医学院附属第一医院
• 李 磊 | 西安交通大学第一附属医院
• 李长福 | 哈尔滨医科大学附属肿瘤医院
• 梁朝朝 | 安徽医科大学附属第一医院
• 廖 洪 | 四川省肿瘤医院
• 林天歆 | 中山大学孙逸仙纪念医院
• 刘 皓 | 中山大学孙逸仙纪念医院
• 刘 明 | 北京医院
• 刘 南 | 重庆大学附属肿瘤医院
• 蒙清贵 | 广西医科大学附属肿瘤医院
• 牛远杰 | 天津医科大学第二医院
• 齐 琳 | 中南大学湘雅医院
• 史本康 | 山东大学齐鲁医院
• 涂新华 | 江西省肿瘤医院
• 王保军 | 中国人民解放军总医院
• 王春喜 | 吉林大学第一医院
• 王启林 | 云南省肿瘤医院
• 王增军 | 江苏省人民医院
• 魏 强 | 四川大学华西医院
• 魏少忠 | 湖北省肿瘤医院
• 肖 峻 | 中国科学技术大学附属第一院/安徽省立医院
• 邢金春 | 厦门大学附属第一医院
• 徐万海 | 哈尔滨医科大学附属第四医院
• 徐子程 | 江苏省肿瘤医院
• 叶定伟 | 复旦大学附属肿瘤医院
• 岳中瑾 | 兰州大学第二医院
• 张爱莉 | 河北医科大学第四医院
• 章小平 | 华中科技大学同济医学院附属协和医院
• 种 铁 | 西安交通大学第二附属医院
• 周芳坚 | 中山大学肿瘤防治中心
• 朱绍兴 | 浙江省肿瘤医院
• 朱 耀 | 复旦大学附属肿瘤医院
• 邹 青 | 江苏省肿瘤医院

执笔专家

• 朱 耀 | 复旦大学附属肿瘤医院

［参考文献］

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.

[2] International Agency for Research on Cancer. Estimated age-standardized incidence rates (World) in 2020, World, both sexes, all ages[EB/OL]. https://gco.iarc.fr/today.[2022-09-29].

[3] ZHU Y, MO M, WEI Y, et al. Epidemiology and genomics of prostate cancer in Asian men[J]. Nat Rev Urol, 2021, 18(5): 282-301.

[4] CHEN W Q, ZHENG R S, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.

[5] WANG Y C, LU D S, CHUNG Y J, et al. Genetic structure, divergence and admixture of Han Chinese, Japanese and Korean populations[J]. Hereditas, 2018, 155: 19.

[6] YOSHINO T, ARGILÉS G, OKI E, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer[J]. Ann Oncol, 2021, 32(12): 1496-1510.

[7] KITAGAWA Y, NAMIKI M. Prostate-specific antigen-based population screening for prostate cancer: Current status in Japan and future perspective in Asia[J]. Asian J Androl, 2015, 17(3): 475-480.

[8] LI J, XU C L, LEE H J, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations[J]. Nature, 2020, 580(7801): 93-99.

[9] DESAI M M, CACCIAMANI G E, GILL K, et al. Trends in incidence of metastatic prostate cancer in the US[J]. JAMA Netw Open, 2022, 5(3): e222246.

[10] BURGESS L, ALDRIGHETTI C M, GHOSH A, et al. Association of the USPSTF grade D recommendation against prostate-specific antigen screening with prostate cancer-specific mortality[J]. JAMA Netw Open, 2022, 5(5): e2211869.

[11] US PREVENTIVE SERVICES TASK FORCE, GROSSMAN D C, CURRY S J, et al. Screening for prostate cancer: US preventive services task force recommendation statement[J]. JAMA, 2018, 319(18): 1901-1913.

[12] VAN POPPEL H, ALBREHT T, BASU P, et al. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future[J]. Nat Rev Urol, 2022, 19(9): 562-572.

[13] CHEN R, REN S C, CHINESE PROSTATE CANCER CONSORTIUM, et al. Prostate cancer in Asia: A collaborative report[J]. Asian J Urol, 2014, 1(1): 15-29.

[14] 马春光, 叶定伟, 李长岭, 等. 前列腺癌的流行病学特征及晚期一线内分泌治疗分析[J]. 中华外科杂志, 2008, 46(12): 921-925.

MA C G, YE D W, LI C L, et al. Epidemiology of prostate cancer from three centers and analysis of the first-fine hormonal therapy for the advanced disease[J]. Chin J Surg, 2008, 46(12): 921-925.

[15] UEMURA H, YE D W, KANESVARAN R, et al. United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia[J]. BJU Int, 2020, 125(4): 541-552.

[16] 中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会(CSCO)前列腺癌诊疗指南-2021[M]. 北京: 人民卫生出版社, 2021.

Organization of Guidelines Working Committee of Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) guidelines for diagnosis and treatment of prostate cancer-2021[M]. Beijing: People's Health Publishing House, 2021.

[17] KANESVARAN R, CASTRO E, WONG A, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer[J]. ESMO Open, 2022, 7(4): 100518.

[18] EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2021. ISBN 978-94-92671-13-4.[J].

[19] 中国抗癌协会泌尿男生殖系肿瘤专业委员会, 朱　耀. 2018版转移性前列腺癌诊治中国专家共识[J]. 中华外科杂志, 2018(9): 646-652.

Chinese Anticancer Association Genitourinary Oncology Committee, ZHU Y. Chinese experts consensus on the treatment of metastatic prostate cancer 2018 edition[J]. Chin J Surg, 2018(9): 646-652.

[20] Hormone therapy for prostate cancer[EB/OL]. https://www.cancer.org/cancer/prostate-cancer/treating/hormone-therapy.html[2022-09-30].

[21] VIRGO K S, RUMBLE R B, DE WIT R, et al. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update[J]. J Clin Oncol, 2021, 39(11): 1274-1305.

[22] DAI B, ZHANG S, WAN F N, et al. Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase Ⅱ randomized controlled trial[J]. Eur Urol Oncol, 2022, 5(5): 519-525.

[23] HELLMAN S, WEICHSELBAUM R R. Oligometastases[J]. J Clin Oncol, 1995, 13(1): 8-10.

[24] KATIPALLY R R, PITRODA S P, JULOORI A, et al. The oligometastatic spectrum in the era of improved detection and modern systemic therapy[J]. Nat Rev Clin Oncol, 2022, 19(9): 585-599.

[25] CONNOR M J, SMITH A, MIAH S, et al. Targeting oligometastasis with stereotactic ablative radiation therapy or surgery in metastatic hormone-sensitive prostate cancer: A systematic review of prospective clinical trials[J]. Eur Urol Oncol, 2020, 3(5): 582-593.

[26] ASHRAM S, BAHIG H, BARRY A, et al. Planning trade-offs for SABR in patients with 4 to 10 metastases: A substudy of the SABR-COMET-10 randomized trial[J]. Int J Radiat Oncol Biol Phys, 2022, 114(5): 1011-1015.

[27] FAROLFI A, HADASCHIK B, HAMDY F C, et al. Positron emission tomography and whole-body magnetic resonance imaging for metastasis-directed therapy in hormone-sensitive oligometastatic prostate cancer after primary radical treatment: A systematic review[J]. Eur Urol Oncol, 2021, 4(5): 714-730.

[28] STEUBER T, JILG C, TENNSTEDT P, et al. Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: A multi-institutional case-control study[J]. Eur Urol Focus, 2019, 5(6): 1007-1013.

[29] DE BLESER E, JERECZEK-FOSSA B A, PASQUIER D, et al. Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: A multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy[J]. Eur Urol, 2019, 76(6): 732-739.

[30] GLICKSMAN R M, METSER U, VINES D, et al. Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: A prospective phase II trial testing the oligometastasis hypothesis[J]. Eur Urol, 2021, 80(3): 374-382.

[31] PHILLIPS R, SHI W Y, DEEK M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial[J]. JAMA Oncol, 2020, 6(5): 650-659.

[32] OST P, REYNDERS D, DECAESTECKER K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial[J]. J Clin Oncol, 2018, 36(5): 446-453.

[33] EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2022. ISBN 978-94-92671-16-5. 2022.

[34] 中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南-2022[M]. 北京: 人民卫生出版社, 2022.

Organization of Guidelines Working Committee of Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) breast cancer diagnosis and treatment guideline-2022 [M] Beijing: People's Health Publishing House, 2022.

[35] GILLESSEN S, ARMSTRONG A, ATTARD G, et al. Management of patients with advanced prostate cancer: Report from the advanced prostate cancer consensus conference 2021[J]. Eur Urol, 2022, 82(1): 115-141.

[36] CECI F, OPREA-LAGER D E, EMMETT L, et al. E-PSMA: The EANM standardized reporting guidelines v1.0 for PSMA-PET[J]. Eur J Nucl Med Mol Imaging, 2021, 48(5): 1626-1638.

[37] EIBER M, HERRMANN K, CALAIS J, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): Proposed miTNM classification for the interpretation of PSMA-ligand PET/CT[J]. J Nucl Med, 2018, 59(3): 469-478.

[38] EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2020. ISBN 978-94-92671-07-3. 2020.

[39] Preliminary results in APCCC 2022[EB/OL]. www.apccc.org. [2022-09-30].

[40] SUNDAHL N, GILLESSEN S, SWEENEY C, et al. When what You see is not always what You get: Raising the bar of evidence for new diagnostic imaging modalities[J]. Eur Urol, 2021, 79(5): 565-567.

[41] BARBATO F, FENDLER W P, RAUSCHER I, et al. PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease[J]. J Nucl Med, 2021, 62(12): 1747-1750.

[42] FIZAZI K, TRAN N, FEIN L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer[J]. N Engl J Med, 2017, 377(4): 352-360.

[43] KYRIAKOPOULOS C E, CHEN Y H, CARDUCCI M A, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial[J]. J Clin Oncol, 2018, 36(11): 1080-1087.

[44] ABIDA W, ARMENIA J, GOPALAN A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making[J]. JCO Precis Oncol, 2017, 2017: PO.17.00029.

[45] SANDHU S, MOORE CM, CHIONG E, et al. Prostate cancer[J]. Lancet, 2021, 398(10305): 1075-1090.

[46] DEEK M P, VAN DER EECKEN K, PHILLIPS R, et al. The mutational landscape of metastatic castration-sensitive prostate cancer: The spectrum theory revisited[J]. Eur Urol, 2021, 80(5): 632-640.

[47] ZHU Y, WEI Y, ZENG H, et al. Inherited mutations in Chinese men with prostate cancer[J]. J Natl Compr Canc Netw, 2021, 20(1): 54-62.

[48] GIRI V N, KNUDSEN K E, KELLY W K, et al. Implementation of germline testing for prostate cancer: Philadelphia prostate cancer consensus conference 2019[J]. J Clin Oncol, 2020, 38(24): 2798-2811.

[49] 中国抗癌协会泌尿男生殖系统肿瘤专业委员会, 中国肿瘤医院泌尿肿瘤协作组. 泌尿男生殖系统肿瘤多学科团队综合诊治组织与实施规范中国专家共识[J]. 中国癌症杂志, 2017, 27(11): 917-920.

Urogenital Cancer Committee of China Anti-Cancer Association, Urogenital Cancer Cooperative Group of China Cancer Hospitals. Chinese expert consensus on the organization and implementation of comprehensive diagnosis and treatment of urogenital tumors by multidisciplinary teams[J]. China Oncol, 2017, 27(11): 917-920.

[50] KENCH J G, AMIN M B, BERNEY D M, et al. WHO Classification of Tumours fifth edition: Evolving issues in the classification, diagnosis, and prognostication of prostate cancer[J]. Histopathology, 2022, 81(4): 447-458.

[51] ZAFFUTO E, POMPE R, ZANATY M, et al. Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: A SEER database analysis[J]. Clin Genitourin Cancer, 2017, 15(5): e793-e800.

[52] NETTO G J, AMIN M B, BERNEY D M, et al. The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors[J]. Eur Urol, 2022, 82(5): 469-482.

[53] ZHAO J G, LIU J D, SUN G X, et al. The prognostic value of the proportion and architectural patterns of intraductal carcinoma of the prostate in patients with de novo metastatic prostate cancer[J]. J Urol, 2019, 201(4): 759-768.

[54] DINERMAN B F, KHANI F, GOLAN R, et al. Population-based study of the incidence and survival for intraductal carcinoma of the prostate[J]. Urol Oncol, 2017, 35(12): 673.e9-673673.e14.

[55] PORTER L H, LAWRENCE M G, ILIC D, et al. Systematic review links the prevalence of intraductal carcinoma of the prostate to prostate cancer risk categories[J]. Eur Urol, 2017, 72(4): 492-495.

[56] ZHAO T, LIAO B H, YAO J, et al. Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer? [J]. Prostate, 2015, 75(3): 225-232.

[57 WANG Z P, ZHU S, ZHAO J G, et al. The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer[J]. Prostate, 2021, 81(15): 1191-1201.

[58] ANTONARAKIS E S, SHAUKAT F, ISAACSSON VELHO P, et al. Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations[J]. Eur Urol, 2019, 75(3): 378-382.

[59] BÖTTCHER R, KWELDAM C F, LIVINGSTONE J, et al. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations[J]. BMC Cancer, 2018, 18(1): 8.

[60] SCHWEIZER M T, ANTONARAKIS E S, BISMAR T A, et al. Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations[J]. JCO Precis Oncol, 2019, 3: PO.18.00327.

[61] CHUA M L K, LO W, PINTILIE M, et al. A prostate cancer “nimbosus”: Genomic instability and SChLAP1 dysregulation underpin aggression of intraductal and cribriform subpathologies[J]. Eur Urol, 2017, 72(5): 665-674.

[62] ZHAO J G, SUN G X, ZHU S, et al. Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate[J]. BJU Int, 2022, 129(3): 345-355.

[63] TAYLOR R A, FRASER M, LIVINGSTONE J, et al. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories[J]. Nat Commun, 2017, 8: 13671.

[64] ISAACSSON VELHO P, SILBERSTEIN J L, MARKOWSKI M C, et al. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer[J]. Prostate, 2018, 78(5): 401-407.

[65] FIZAZI K, FOULON S, CARLES J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2  ×  2 factorial design[J]. Lancet, 2022, 399(10336): 1695-1707.

[66] SMITH M R, HUSSAIN M, SAAD F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer[J]. N Engl J Med, 2022, 386(12): 1132-1142.

[67] DAVIS I D, MARTIN A J, ZIELINSKI R R, et al. Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC)[J]. J Clin Oncol, 2022, 40(17_suppl): LBA5004.

[68] MAIORANO B A, DE GIORGI U, ROVIELLO G, et al. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis[J]. ESMO Open, 2022, 7(5): 100575.

[69] ROY S, SAYYID R, SAAD F, et al. Addition of docetaxel to androgen receptor axis-targeted therapy and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis[J]. Eur Urol Oncol, 2022, 5(5): 494-502.

[70] FALLARA G, ROBESTI D, NOCERA L, et al. Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis[J]. Cancer Treat Rev, 2022, 110: 102441.

[71] YANAGISAWA T, RAJWA P, THIBAULT C, et al. Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis[J]. Eur Urol, 2022, 82(6): 584-598.

[72] CICCARESE C, IACOVELLI R, STERNBERG C N, et al. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis[J]. Eur J Cancer, 2022, 173: 276-284.

[73] PARKER C C, JAMES N D, BRAWLEY C D, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial[J]. Lancet, 2018, 392(10162): 2353-2366.

[74] ALI A, HOYLE A, HARAN Á M, et al. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: A secondary analysis of a randomized clinical trial[J]. JAMA Oncol, 2021, 7(4): 555-563.

[75] PARKER C C, JAMES N D, BRAWLEY C D, et al. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial[J]. PLoS Med, 2022, 19(6): e1003998.

[76] REYES D K, TROCK B J, TRAN P T, et al. Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer[J]. Med Oncol, 2022, 39(5): 63.

[77] REYES D K, ROWE S P, SCHAEFFER E M, et al. Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer[J]. Med Oncol, 2020, 37(7): 60.

[78] SCHER H I, MORRIS M J, STADLER W M, et al. Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3[J]. J Clin Oncol, 2016, 34(12): 1402-1418.

[79] BEER T M, ARMSTRONG A J, RATHKOPF D E, et al. Enzalutamide in metastatic prostate cancer before chemotherapy[J]. N Engl J Med, 2014, 371(5): 424-433.

[80] RYAN C J, SMITH M R, DE BONO J S, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy[J]. N Engl J Med, 2013, 368(2): 138-148.

[81] FIZAZI K, JONES R, OUDARD S, et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5[J]. J Clin Oncol, 2015, 33(7): 723-731.

[82] NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN). NCCN Guidelines Version 4.2022 Prostate Cancer[EB/OL]. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf[2022-09-29].

[83] HUSSAIN M, TANGEN C M, HIGANO C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162)[J]. J Clin Oncol, 2006, 24(24): 3984-3990.

[84] HARSHMAN L C, CHEN Y H, LIU G, et al. Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel[J]. J Clin Oncol, 2018, 36(4): 376-382.

[85] MATSUBARA N, CHI K N, ÖZGÜROĞLU M, et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: Post hoc analysis of phase 3 LATITUDE study[J]. Eur Urol, 2020, 77(4): 494-500.

[86] SAAD F, HUSSAIN M H A, TOMBAL B F, et al. Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial[J]. J Clin Oncol, 2022, 40(16_suppl): 5078.

[87] GRAVIS X, et al. Oral presentation at ESMO congress[C]. 2022, September 9-13; Paris, France.

[88] CHOWDHURY S, et al. Oral presentation at AUA Annual Meeting (Virtual), May 15-18, 2020. Abstract PD10.

[89] SMALL EJ, CHI KN, CHOWDHURY S, et al. Poster presentation at ASCO GU 2022; February 17-19, 2022; San Francisco, California; poster D1.

[90] CHI KN, SAAD F, CHOWDHURY S, et al. PD34-Prostate-Specific Antigen Kinetics In Patients With Advanced Prostate Cancer Treated With Apalutamide: Results From The TITAN And SPARTAN Studies. Journal of Urology, 2021. 206(Suppl3): e587-e587.

[91] SANTIS D, GILLESSEN S, GRUMMET J, et al. Eau-eanm-estro esur isup siog-guidelines-on-prostate-cancer-2021, 2021.

[92] BRYCE A H, CHEN Y H, LIU G, et al. Patterns of cancer progression of metastatic hormone-sensitive prostate cancer in the ECOG3805 CHAARTED trial[J]. Eur Urol Oncol, 2020, 3(6): 717-724.

[93] ARMSTRONG A J, MOTTET N, IGUCHI T, et al. Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of ARCHES[J]. J Clin Oncol, 2022, 40(16_suppl): 5072.

[94] European Association of Urology. EAU-EANM - ESTRO -ESUR - ISUP - SIOG Guidelines on Prostate Cancer[J]. 2022.

[95] JUNG J H, HONG C M, JO I, et al. Reliability of alkaline phosphatase for differentiating flare phenomenon from disease progression with bone scintigraphy[J]. Cancers (Basel), 2022, 14(1): 254.

[96] SCHER HI, MORRIS MJ, STADLER WM, et al. The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC)[J]. 2015, 33(15_suppl): 5000-5000.

[97] SWAMI U, SINNOTT J A, HAALAND B, et al. Treatment pattern and outcomes with systemic therapy in men with metastatic prostate cancer in the real-world patients in the United States[J]. Cancers (Basel), 2021, 13(19): 4951.

[98] CHI K N, CHOWDHURY S, BJARTELL A, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase III TITAN study[J]. J Clin Oncol, 2021, 39(20): 2294-2303.

[99] ARMSTRONG A J, AZAD A A, IGUCHI T, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer[J]. J Clin Oncol, 2022, 40(15): 1616-1622.

[100] EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1. 2018.

[101] SWAMI U, HONG A, EL-CHAAR N N, et al. Underutilization of standard of care (SOC) treatment intensification in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) by specialty[J]. J Clin Oncol, 2022, 40(6_suppl): 183.

[102] TEWARI A K, GILLESSEN S, SWEENEY C J. Metastatic prostate cancer: In search of more granularity[J]. J Clin Oncol, 2021, 39(26): 2968-2969.

[103] VOGL U M, BEER T M, DAVIS I D, et al. Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings[J]. Eur J Cancer, 2022, 160: 24-60.

（来源：中国癌症杂志）

声 明

凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。